Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 22 of 125 for:    "Depressive Disorder" [DISEASE] AND Behavioral | ( Map: Spain )

Trehalose as add-on Therapy in Bipolar Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02800161
Recruitment Status : Recruiting
First Posted : June 15, 2016
Last Update Posted : July 24, 2019
Sponsor:
Collaborator:
Stanley Medical Research Institute
Information provided by (Responsible Party):
Consorcio Centro de Investigación Biomédica en Red, M.P.

Brief Summary:
The ongoing research on bipolar disorder (BD) has highlighted its pervasive and debilitating nature, characterized by lifelong recurrent episodes and residual intraepisodic symptomatology. Epidemiologic, comorbidity, cost-of illness, and mortality studies have reported dramatic illness-associated morbidity and premature mortality in bipolar patients. The efficacy and safety of antidepressant drug treatment in BD is the subject of long-standing debate based on a scientific literature that is limited and inconsistent. The evidence base for the use of antidepressant drugs in BD is strikingly weak, and there is insufficient evidence for treatment benefits with antidepressants combined with mood stabilizers. The need to develop new agents for the treatment of depression, and in particular bipolar depression, with better efficacy and/or tolerability, remains unmet. In the past years there has been increasing interest in the health benefits of supplemental and/or dietary substances in the treatment and prevention of depression. The disaccharide trehalose protects cells from hypoxic and anoxic injury and suppresses protein aggregation. In vivo studies with trehalose show cellular and behavioural beneficial effects in animal models of neurodegenerative diseases. Moreover, trehalose was shown to enhance autophagy, a process that had been recently suggested to be involved in the therapeutic action of antidepressant and mood-stabilizing drugs. In fact, trehalose may have antidepressant-like properties and that the trehalose induced behavioral changes are possibly related to trehalose effects to enhance autophagy. Furthermore, preliminary data indicates that trehalose also augments lithium effects in animal models (mice). Based on this hypothesis, this project aims to conduct a study to assess the efficacy and tolerability of trehalose as adjunctive treatment to lithium in bipolar depression.

Condition or disease Intervention/treatment Phase
Bipolar Disorder Bipolar Depression Drug: Trehalose Drug: Maltose Phase 3

Detailed Description:

This is an investigator-initiated parallel group pilot study. All patients will give a signed informed consent prior to initiation of any study procedure.

Study setting: This unicentric pilot study will be carried out at the Bipolar Disorder Programme of the Hospital Clinic, University of Barcelona. Over 700 Bipolar Disorder patients are currently treated by Bipolar Disorders Program of the Hospital Clinic and University of Barcelona, a tertiary center providing integrated care for patients from a specific catchment area as well as difficult-to-treat bipolar patients derived from all over Spain, as already described elsewhere.

Patients are considered to be enrolled in the study when they sign the informed consent. Patients are considered to be randomized when they are assigned to receive either trehalose or maltose. It is expected that at least 60 patients will be randomly assigned in a 1:1 ratio of trehalose 70g to placebo (maltose 70g). Patients will receive no economic compensation for their participation in the study.

Patients will be evaluated at baseline and at weeks 2, 4 and 6. At baseline, patients will receive explanations regarding the study; after signing the informed consent patients will be interviewed by the study psychiatrist and will be administered the study scales M.I.N.I. International Neuropsychiatric Interview-Plus (MINI-Plus), Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Rating scale for Depression (HAMD), Clinical Global Impression-Bipolar Disorder (CGI-BP), World Health Organization-well being (WHO-wb), Functioning Assessment Short Test (FAST), Cognitive complaints in bipolar disorder rating assessment (COBRA). Furthermore, patients will undergo routine blood analysis including glycaemia, thyroid function (T3, T4, TSH) as well as lithaemia, at baseline and at week 6. At weeks 2 and 4 patients will be administered MADRS, HAMD, CGI-BP, WHO-wb and FAST scales, and eventual side effects will be recorded. At week 6, patients will be interviewed and MADRS, HAMD, CGI-BP, and FAST and will be administered and side effects recorded. At the final visit (week 6), patients will undergo a clinical interview, followed by administration of MADRS, CGI-BP, WHO-wb, COBRA and FAST scales. Full blood analysis will be performed.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Trehalose as add-on Therapy in Bipolar Depression
Study Start Date : June 2016
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder

Arm Intervention/treatment
Active Comparator: Trehalose
Trehalose 70g/die
Drug: Trehalose
Trehalose 70g/die

Placebo Comparator: Placebo
Maltose 70g/die
Drug: Maltose
Maltose 70g/die




Primary Outcome Measures :
  1. Primary Outcome: efficacy assessed with the Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: Mean change from baseline to endpoint (week 8) ]
    The primary outcome measure is evaluation of efficacy in terms of the mean change from baseline in the total score of the Montgomery-Asberg Depression Rating Scale (MADRS) after the 8 weeks of the study.

  2. Primary Outcome: efficacy assessed with the Hamilton Rating scale for Depression (HAMD) [ Time Frame: Mean change from baseline to endpoint (week 8) ]
    The primary outcome measure is evaluation of efficacy in terms of the mean change from baseline in the total score of the Hamilton Rating scale for Depression (HAMD) after the 8 weeks of the study.


Secondary Outcome Measures :
  1. Secondary Outcome: response to treatment defined as a reduction of at least 50% on the MADRS (Montgomery-Asberg Depression Rating Scale). [ Time Frame: Mean change from baseline to endpoint (week 8) ]
    Secondary outcome measures will be response treatment defined as a reduction of at least 50% on the MADRS (Montgomery-Asberg Depression Rating Scale) from baseline to endpoint determination at 8 week.

  2. Secondary Outcome: response to treatment defined as a reduction of at least 50% on the HAMD (Hamilton Rating scale for Depression). [ Time Frame: Mean change from baseline to endpoint (week 8) ]
    Secondary outcome measures will be response treatment defined as a reduction of at least 50% on the HAMD (Hamilton Rating scale for Depression) from baseline to endpoint determination at 8 week.

  3. Secondary Outcome: response to treatment defined as a reduction of at least 50% on the CGI-BP (Clinical Global Impression-Bipolar Disorder). [ Time Frame: Mean change from baseline to endpoint (week 8) ]
    Secondary outcome measures will be response treatment defined as a reduction of at least 50% on the CGI-BP (Clinical Global Impression-Bipolar Disorder) from baseline to endpoint determination at 8 week.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Bipolar I and II patients aged between 18 and 65.
  • Bipolar disorder type I or II and a current major depressive episode (Montgomery-Asberg Depression Rating Scale (MADRS) ≥18.
  • Clinical Global Impression-Bipolar version (CGI-BP)≥4.
  • All patients need to be receiving lithium at a steady dose (0.5-1.2 mmol/L) during at least 2 weeks prior to the study.
  • Other mood stabilizers added to lithium are permitted but at steady dose during at least 2 weeks prior to the study.
  • Other psychopharmacological treatments should be at stable dose 2 weeks prior to the study.

Exclusion Criteria:

  • Exclusion criteria will be the presence of psychotic features, severe suicidal ideation (score of ≥5 on item 10 of MADRS).
  • A severe personality disorder suggesting noncompliance.
  • Diabetes Mellitus, any severe neurologic or other somatic illness and the use of somatic medication that could influence the mood.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02800161


Contacts
Layout table for location contacts
Contact: Eduard Vieta, MD, PhD +34932275400 ext 3130 EVIETA@clinic.ub.es
Contact: Dina Popovic, MD, PhD +34932275400 ext 3130 POPOVIC@clinic.ub.es

Locations
Layout table for location information
Spain
Hospital Clinic of Barcelona Recruiting
Barcelona, Spain, 08036
Contact: Dina Popovic, MD, PhD    +34932275400 ext 3130    POPOVIC@clinic.ub.es   
Sponsors and Collaborators
Consorcio Centro de Investigación Biomédica en Red, M.P.
Stanley Medical Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Eduard Vieta, MD,PhD Principal Investigator CIBER

Layout table for additonal information
Responsible Party: Consorcio Centro de Investigación Biomédica en Red, M.P.
ClinicalTrials.gov Identifier: NCT02800161     History of Changes
Other Study ID Numbers: #14t-012
First Posted: June 15, 2016    Key Record Dates
Last Update Posted: July 24, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Depressive Disorder
Bipolar Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Bipolar and Related Disorders